Patents by Inventor Tetsuro Ikekawa

Tetsuro Ikekawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Physiologically active substance EEM-S originating in mushrooms, process for producing the same and drugs
    Patent number: 6783771
    Abstract: EEM-S obtained by extracting with hot water or a lower alcohol at least one mushroom selected from among Lentinus edodes, Flammulina velutipes, Hypsizygus marmoreus, Pleurotus ostreatus, Pholiota nameko, Grifola fondosa, Volvariella speciosa ver. speciosa, Lyophllum decastes, blanc du pays, Tricholoma matsutake, Ganoderma lucidum and Phellinus yucatensis, treating the obtained extract by the molecular sieve method and thus eliminating low-molecular-weight and high-molecular-weight fractions: and preparations thereof. This EEM-S exerts physiological effects such as anticancer, immunopotentiating, antioxidative, hypotensive and hypoglycemic effects.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: August 31, 2004
    Assignee: Life Science Laboratories Co., Ltd.
    Inventors: Tetsuro Ikekawa, Akiko Ikekawa, Fumitake Shimada
  • Physiologically active substance eem-s originating in mushroms, process for producing the same and drugs
    Publication number: 20030012798
    Abstract: EEM-S obtained by extracting with hot water or a lower alcohol at least one mushroom selected from among Lentinus edodes, Flammulina velutipes, Hypsizygus marmoreus, Pleurotus ostreatus, Pholiota nameko, Grifola fondosa, Volvariella speciosa ver. speciosa, Lyophllum decastes, blanc du pays, Tricholoma matsutake, Ganoderma lucidum and Phellinus yucatensis, treating the obtained extract by the molecular sieve method and thus eliminating low-molecular-weight and high-molecular-weight fractions: and preparations thereof. This EEM-S exerts physiological effects such as anticancer, immunopotentiating, antioxidative, hypotensive and hypoglycemic effects.
    Type: Application
    Filed: July 12, 2002
    Publication date: January 16, 2003
    Inventors: Tetsuro Ikekawa, Akiko Ikekawa, Fumitake Shimada
  • Carcinostatic compound and production thereof
    Patent number: 5616609
    Abstract: Described are stelleramacrin A and stelleramacrin B represented by the following formulas (I) and (II), respectively: ##STR1## a process for the preparation thereof; and anticancer agents containing either of them as an active ingredient.Therapeutics for solid cancer, said therapeutics containing either of gnidimacrin or pimelea factor P.sub.2 as an active ingredient, are also described.
    Type: Grant
    Filed: February 8, 1994
    Date of Patent: April 1, 1997
    Inventors: Tetsuro Ikekawa, Nobuo Ikekawa
  • 13-propylberberine salts
    Patent number: 4761477
    Abstract: A 13-propylberberine salt, which is represented by the following general formula (I): ##STR1## wherein X.sup.- means HSO.sub.4 or H.sub.2 PO.sub.4, has strong inhibitory effect against secretion, good stability and high water solubility. Its effects are shown promptly after its oral administration.
    Type: Grant
    Filed: November 27, 1985
    Date of Patent: August 2, 1988
    Assignee: SS Pharmaceutical Co., Ltd.
    Inventors: Tetsuro Ikekawa, Fumitake Shimada, Jong-Chol Cyong, Kazuo Uebaba
  • Process for producing emitanin
    Patent number: 4177108
    Abstract: EMITANIN having antitumor activity is produced by inoculating mycelia of Tricholoma matsutake, Tricholoma baka-matsutake, Volvariella volvacea or Tremella fuciformis in a medium for growing mycelia and fermenting the grown mycelia in a liquid medium containing a carbohydrate and a nitrogen source and isolating solid substance of mycelia from a broth and extracting the solid substance of mycelia and isolating the active ingredient.
    Type: Grant
    Filed: February 27, 1978
    Date of Patent: December 4, 1979
    Inventors: Koji Sakakida, Tetsuro Ikekawa